EAN 2024 | Developing the SynNeurGe criteria for use in Parkinson’s research

Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany, discusses proposed clinical criteria for classifying Parkinson’s disease (PD) to distinguish between different types of the disease to better select patients for clinical trials investigating targeted interventions. Prof. Outeiro describes the three-component system, known as the SynNeurGe criteria, which includes the presence or absence of pathological α-synuclein (S) in tissues or cerebrospinal fluid (CSF) determined by the seed amplification assay; evidence of underlying neurodegeneration (N) defined by neuroimaging procedures; and presence of pathogenic gene variants (G) that cause or strongly predispose an individual to PD. This system is currently being refined and validated for research purposes, with the goal of eventually developing a clinically usable tool for clinicians. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.